哌拉西林/他唑巴坦治疗急性脑卒中相关性肺炎36例

Piperacillin/tazobactam in treatment of 36 patients with acute stroke-associated pneumonia

目的评价哌拉西林/他唑巴坦治疗急性脑卒中相关性肺炎的疗效与安全性。方法 36例因急性脑卒中而并发经病原学证实的卒中相关性肺炎患者经验性选择哌拉西林/他唑巴坦治疗,疗程为14d,治疗后复查痰培养,并观察临床改善情况。结果哌拉西林/他唑巴坦治疗急性脑卒中相关性肺炎治疗有效率91.7%,细菌清除率89.0%,不良反应率2.8%。结论哌拉西林/他唑巴坦治疗急性脑卒中相关性肺炎疗效显著,具有高效安全的特点。

OBJECTIVE To evaluate the clinical efficacy and safety of piperacillin/tazobactam in treatment of acute stroke-associated pneumonia. METHODS A total of 36 acute stroke-associated pneumonia patients who were microbiologically diagnosed were treated with piperacillin/tazobactam with the course of 14 days, the sputum culture was re-checked after the treatment, and the clinical improvement was observed. RESULTS The effective rate of treatment with piperacillin/tazobactam was 91.7 %, the bacterial eradication rate was 89.0 %, the incidence of adverse reactions was 2.8%. CONCLUSION Piperacillin/tazobactam is a highly effective and safe agent in the treatment of acute stroke-associated pneumonia.